SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Vertex Pharmaceuticals (VRTX)
An SI Board Since August 1996
Posts SubjectMarks Bans Symbol
1169 64 0 VRTX
Emcee:  David Lieberman Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
1119Anyone following VRTX? I'm expecting news any day now on the request for priDitchdigger-1/1/2011
1118Vertex Provides Update to Ongoing Phase 2 Study Evaluating Combinations of Telaptnsaf-12/21/2010
1117The article is not 'way off-base'. Read again from the original post anDoctor Zeus-12/12/2010
1116The blogger’s contention that VRTX is a “binary event” company is way off-base, DewDiligence_on_SI112/11/2010
1115Interesting Article on Vertex I found this article interesting. It relates to tDoctor Zeus-12/11/2010
1114Vertex Completes New Drug Application for Telaprevir for Hepatitis C - Submissitnsaf-11/28/2010
1113Vertex Announces Plans to Enroll Additional Treatment Arm in Ongoing Phase 2 Comtnsaf-11/28/2010
1112Vertex Pharmaceuticals Announces Start of a Phase 3b Study of Twice-Daily Telaprtnsaf-10/25/2010
1111Update on all-oral HCV programs: siliconinvestor.comDewDiligence_on_SI-10/25/2010
1110not too surprising (today's news), but "ugh" nonetheless........ scaram(o)uche-10/25/2010
1109Vertex Pharmaceuticals Initiates Clinical Trial to Evaluate Combination Regimenstnsaf-10/18/2010
1108Telaprevir vs Boceprevir in First- and Second-Line Settings: siliconinvestor.coDewDiligence_on_SI-9/12/2010
1107Telaprevir phase-3 REALIZE results formatted for enhanced readability: siliconiDewDiligence_on_SI-9/12/2010
1106not even going to TRY to format the data..... finance.yahoo.com (snip) The sascaram(o)uche-9/7/2010
1105Phase 3 ILLUMINATE Study Supports 24-Week Telaprevir-Based Therapy Within a Resptnsaf-8/11/2010
1104<b>Telaprevir vs Boceprevir in First- and Second-Line Settings</b> DewDiligence_on_SI-8/4/2010
1103MRK Reports Data from Phase-3 Boceprevir Trials: siliconinvestor.comDewDiligence_on_SI-8/4/2010
1102<i>>what are Telaprevir's main competition as far as other drugs inDewDiligence_on_SI-5/27/2010
1101any predictions on when and where we bottom out? Also what are Telaprevir'srobmeister-5/27/2010
1100Never, ever would have thought to sell on that news. The potential that 222 wilscaram(o)uche15/26/2010
109975% is right smack in the middle of the 65-85% range Josh Boger described four yDewDiligence_on_SI-5/26/2010
109875% of Treatment-Naïve Patients with Chronic Hepatitis C Achieve SVR (Viralscaram(o)uche-5/25/2010
1097UPDATE 2-Vertex to begin telaprevir application this summer Wed Apr 21, 2010 5:0tnsaf-4/22/2010
109659 Percent of Patients Overall Achieved SVR with Telaprevir-Based Regimens in Sttnsaf-4/16/2010
1095Hepatitis C Virus Polymerase Inhibitor VX-222 Reduced Viral Levels Over Three Datnsaf-4/16/2010
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News